Production (Stage)
Gain Therapeutics, Inc.
GANX
$1.73
-$0.07-3.89%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -77.56% | 3,496.80% | |||
| Gross Profit | 77.56% | -3,496.80% | |||
| SG&A Expenses | 0.38% | 16.63% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 31.23% | -25.25% | |||
| Operating Income | -31.23% | 25.25% | |||
| Income Before Tax | -35.73% | 27.07% | |||
| Income Tax Expenses | -80.09% | 4,488.18% | |||
| Earnings from Continuing Operations | -20.22% | 16.00% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -20.22% | 16.00% | |||
| EBIT | -31.23% | 25.25% | |||
| EBITDA | -31.31% | 25.30% | |||
| EPS Basic | -16.10% | 19.57% | |||
| Normalized Basic EPS | -31.11% | 30.17% | |||
| EPS Diluted | -16.10% | 19.57% | |||
| Normalized Diluted EPS | -31.11% | 30.17% | |||
| Average Basic Shares Outstanding | 3.54% | 4.42% | |||
| Average Diluted Shares Outstanding | 3.54% | 4.42% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||